Centene Corp (CNC)

Rating: HOLD

HOLD (5-tier) · high-risk optionality · conviction: low

EPS basis for the forward P/E and all scenario multiples: consensus forward EPS (broker-adjusted, non-GAAP).

Methodology: Valuation triangulated across five independent anchors — Monte Carlo (Student-t + regime switching), an independent DCF, peer re-rating, a sum-of-parts, and a scenario-weighted PWEV. Figures reconciled to Alpha Vantage 2026-06-27. Each chart below sits with the part of the thesis it evidences.

General research for a skeptical institutional reader. Not personalised investment advice; no position sizing or trade instructions. Figures as of the analysis date; verify before acting.

Investment Committee Summary

📎 Download the full model (Excel) — DCF line items, scenarios, sensitivity, assumptions, and extended fundamentals.

Rating Bridge

Rating = HOLD because:

• Probability-weighted scenario value implies -3% vs spot
• Monte Carlo median implies -16% vs spot
• DCF fair value implies +58% vs spot
• Bear case (Structural — Medicare/Medicaid Reform / MLR Squeeze) downside is -68% vs spot
• Net: reward/risk of 0.0× is not asymmetric enough for a Buy and not impaired enough for a Sell — hence Hold.

Investment Thesis

At $64.19 (2026-06-27) Centene trades at 18.0x forward earnings against a peer-median 22.2x, on an EV of just 0.15x TTM revenue of $178.3B. The market is pricing a partial margin recovery: it accepts that the FY2025 loss year is past, but not that the ~1.4% mid-cycle operating margin returns durably. The engine's view differs mainly through the DCF anchor — $96.40 per share on a 2% capex-to-revenue bridge and 15x terminal — and the peer P/E anchor near $79, both well above spot. Yet the probability-weighted target is $64.08, essentially at the price, because 37% of the scenario tree sits in cost-trend or reform states where earnings compress towards $1.94 of EPS. HOLD follows: the anchors argue cheap, the tree argues fragile, and the two net out. The single most damaging risk is Medicaid rate inadequacy compounding with federal reform, which drives the $21.32 structural target below the 52-week low of $25.08.

The dashboard below is the whole argument on one page: spot ($66) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The steelman bear is structural, not cyclical. Centene's book is concentrated in government lines whose economics are set by legislators, not by underwriting skill. Redeterminations have already stripped healthier members; if enhanced ACA subsidies lapse and Medicaid work requirements bite, the residual pool's acuity rises while the premium base shrinks — margin and revenue fall together. FY2025's $6.7B GAAP net loss (AV cash-flow data) shows how violently a ~1% operating margin swings when trend is mispriced for even one rate cycle. In that state, earnings power settles near $1.94 of EPS, the market pays a distressed 11x, and the stock revisits $21 — below the 52-week low. Nothing in that chain requires management error; it only requires policy to move against the book.

Key Debate

Gross Margin explains 86% of Monte Carlo outcome variance — the single variable that decides which side is right.

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q1): management +0.48 vs analyst floor +0.00 → delta +0.48 (n=19 mgmt / 13 Q&A; 70th pctile across the S&P book, z +0.6).

Flag: TYPICAL — management-vs-analyst tone within the normal cross-sectional range.

News (last 365d, 1000 articles): avg ticker sentiment +0.10 (bullish 16% / bearish 7%)

Scenario Analysis

The tree runs from a structural 'Structural — Medicare/Medicaid Reform / MLR Squeeze' downside ($21) to a 'Bull — Margin Recovery / Re-Rate' bull case ($116); the probability-weighted blend (PWEV $64) is -3% versus spot.

Scenario rationale — what each probability buys (the driver path behind every target):

• Structural — Medicare/Medicaid Reform / MLR Squeeze (20%, $21). Structural impairment — Medicare/Medicaid reform / MLR squeeze: earnings AND the multiple compress together. Target sits below the 52-week low by construction. Drivers — implied_target: 21.32; probability: 0.2.
• Cost-Trend Spike / Rate Inadequacy (17%, $49). Cyclical downturn — membership + premium growth vs medical-cost trend (MLR) + Medicare/Medicaid policy weakens for 1–2 years before normalising. Drivers — implied_target: 49.01; probability: 0.17.
• Base — Membership + Premium Growth (35%, $68). Mid-cycle — normalised membership + premium growth vs medical-cost trend (MLR) + Medicare/Medicaid policy; disciplined capital allocation; steady returns. Drivers — implied_target: 68.07; probability: 0.35.
• Growth — MA / Care-Services (Optum-style) (20%, $92). Upside — MA + care-services growth lifts earnings above mid-cycle; the multiple expands modestly. Drivers — implied_target: 91.89; probability: 0.2.
• Bull — Margin Recovery / Re-Rate (8%, $116). Upside tail — sustained tight conditions or a structural re-rate on MA + care-services growth. Drivers — implied_target: 116.05; probability: 0.08.

Valuation Triangulation

Five anchors — but read them with their basis in mind. The Monte Carlo, the DCF terminal, and the peer re-rate all key off a market multiple, so they are not fully independent; only the discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat five numbers as five independent votes.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

DCF excluded from the weighted blend — diverges >55% from the Monte-Carlo / scenario core. For a high-leverage equity the per-share DCF (enterprise value less large net debt) is hypersensitive to the terminal multiple; a peer re-rate across heterogeneous margins is apples-to-oranges. Shown above for reference; the blend leans on the multiple-discipline and scenario anchors.

Monte Carlo — the distribution, not a point

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $56 and 41% of paths finish above spot. The variance decomposition shows the gross margin is the dominant swing factor (86% of variance). The fundamental driver, not the multiple, sets the spread — a cleaner setup.

DCF — the cash-flow anchor

Independent of the market multiple: a 5-year path, WACC 8.5%, 15x terminal FCF multiple → $105. This anchor is deliberately the heaviest (41%): it is the valuation least hostage to the current multiple regime.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median forward multiple (P/E 22.22x) implies $79. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 12% so the market's mood does not drive the fair value.

Across all anchors the spread is 182% of the median — wide (genuine disagreement — the blend carries low valuation confidence).

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Industry Context — Health Payers Providers

This name sits in the Health Payers Providers as a managed_care. membership + premium growth vs medical-cost trend (MLR) + Medicare/Medicaid policy Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.

Value chain: UNH (managed_care) · CVS (managed_care) · HCA (providers) · ELV (managed_care) · CI (managed_care) · HUM (managed_care) · CNC (managed_care) · DVA (providers) · UHS (providers)

Mapping note: name-level 'Structural — Medicare/Medicaid Reform / MLR Squeeze' (20%) + 'Cost-Trend Spike / Rate Inadequacy' (17%) map to cluster Cost-Trend Spike / Reimbursement-Reform Squeeze (37%); name-level 'Growth — MA / Care-Services (Optum-style)' (20%) + 'Bull — Margin Recovery / Re-Rate' (8%) map to cluster Upside — Margin Recovery / Care-Services (28%) — the cluster row is the SUM of the mapped scenario probabilities, not a different estimate.

On the cluster's key downside — Cost-Trend Spike / Reimbursement-Reform Squeeze () — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.

Structure: Shared State — The health_payers_providers cycle is the shared macro driver. Driver — medical-cost trend (MLR) + utilization + reimbursement/regulation Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 2% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 8.5% · Σ PV(FCF) $12B + PV(terminal) $35B = EV $47B; + net cash → equity $52B ÷ diluted shares 0.50B = $105/share (exit-multiple terminal).

• Gordon (perpetuity-growth) terminal at 2.5% → $114/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
• Incremental ROIC on the forecast capex ≈ 15% vs WACC 8% → above WACC — the build is value-creative.

Peer set

Peer-median fwd P/E → $79; EV/Rev → $199.

Weighted fair-value math

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × op-margin Δ

Tornado — DCF/share swing by driver (widest first)

Company lever — SoP/share vs Managed Care / Health Services multiple (AI re-rating) (base 18x)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Balance Sheet & Liquidity

Balance-sheet data as of 2025-12-31 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 0.1% of revenue; cash conversion (OCF/NI) -76% — cash-backed.

Catalyst Calendar

• 2026-07-28 (~20d) — Quarterly earnings — est. EPS $0.89 (AV EARNINGS_CALENDAR)
• 2026-10-05 (~89d) — 2027 Medicare Advantage Star-ratings and bid results (authored)
• 2026-12-15 (~160d) — 2027 Medicaid rate-cycle / state redetermination true-up outcomes (authored)
• 2027-01-31 (~207d) — FY2027 EPS guidance / margin-recovery framework at Q4 update (authored)

Forecast Track Record

• EPS surprise: beat 87.5% of the last 8 quarters; average surprise +50.8%.

Competitive Moat

Narrow moat. Centene's advantages are Medicaid contract scale and state-relationship incumbency, not durable pricing power — margins are regulator-set and thin (~1.4% mid-cycle op margin); this justifies only a below-market multiple, and falsifiably: if Medicaid MLR stays above target for two-plus quarters or major state contracts are re-bid away, fair value compresses well below the current 18x.

Moat sources:

• Scale in government-sponsored (Medicaid/CHIP/Marketplace/MA) managed care with state-contract incumbency
• Provider-network breadth and state relationships raising re-procurement switching friction
• Weakness: MLR / rates set by regulators and states — limited independent pricing power
• Weakness: contract concentration risk on periodic Medicaid re-bids

Regulatory & Legal Risk

Probabilities and sensitivities are analyst estimates, not market-implied.

Scenario Macro & Key Risks

What the Market Is Pricing In

At the current price, the market pays 14.8× forward EPS, vs the house DCF terminal 15.0×, and a peer median 22.22×. The house DCF sits 58% above spot, so the market is pricing in less than the house case — roughly 7.3pp of revenue CAGR.

Variant perception: the house view is above-consensus, and the thesis is primarily event-driven.

Peer Quality & Weighting

Quality-weighted forward P/E: 20.8× (simple median 22.22×). Direct peers count 100%, segment 50%, broad 25%.

Historical-range cross-check: 52-week range $25–$67, centre $41 (-38% vs spot); spot sits at the 99th percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

Reward/risk compares triangulated upside against the probability-weighted bear target, not the extreme tail. Bull case (Bull — Margin Recovery / Re-Rate): $116.

Assumption Register

Sensitivity-ranked drivers (widest fair-value swing first): Op margin ±3pp (299.0); Revenue CAGR ±3pp (25.0); Terminal × ±15% (21.0); Capex intensity ±15% (9.0); WACC ±1pp (8.0).

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Source Log

Citation coverage: 13/14 mandated claims sourced. Filing URLs are not available via the market-data provider; company statements are cited as 10-K/10-Q via Alpha Vantage.

Load-Bearing Assumptions

DCF: WACC 8%, terminal multiple 15×, FY+5 revenue $241B. Triangulation leans 41% on DCF, 29% on PWEV.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• Consolidated health benefits ratio (HBR/MLR) > 0.915 (2 consecutive prints → Cost-Trend Spike / Reimbursement-Reform Squeeze). At a ~1.4% base operating margin, an HBR sustained above 91.5% erases underwriting profit and moves the book from the Base path onto the Cost-Trend Spike path.
• FY adjusted EPS guidance < 3.5 (single event → Cost-Trend Spike / Reimbursement-Reform Squeeze). A guidance reset below $3.50 falsifies the Base earnings path: the engine's Monte Carlo median EPS is $3.53 and the base scenario is calibrated to ~$4.25; below $3.50 the cost-trend scenario becomes the operative case.
• Medicaid managed-care membership < 12.5 (2 consecutive prints → Cost-Trend Spike / Reimbursement-Reform Squeeze). Membership (millions) sustained below 12.5m signals redetermination and reform attrition beyond contract-exit plans, cutting the premium base that carries the fixed-cost load and validating the structural-reform mechanism.
• ACA marketplace (Ambetter) enrolment < 4.0 (2 consecutive prints → Cost-Trend Spike / Reimbursement-Reform Squeeze). Enrolment (millions) sustained below 4.0m indicates the lapse of enhanced subsidies is stripping out the healthiest cohort, worsening residual-pool acuity and the HBR simultaneously — the exact structural-scenario mechanism.
• Full-year premium and service revenue guidance < 185.0 (single event → Mid-Cycle — Membership & Volume Growth). Guidance ($B) cut below $185B against a $192.6B FY guide falsifies the 6% base growth assumption and indicates the book is shrinking faster than rate catch-up can offset.

Fact / Inference / Speculation

• FACT: Spot $66; 52-week range $25–$67; engine rating HOLD; base-case target $64 (-3%). (source: Alpha Vantage 2026-06-27, 8 July 2026)
• INFERENCE: Triangulated FV $65 (-2% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the cash-flow anchor sits above the multiple-discipline core.
• SPECULATION: At current prices the embedded bet is that Gross Margin keeps surprising favourably — an operating call the next two prints will test.

Recommendation: HOLD

Balanced: triangulated fair value $81 (+23% vs spot); the outcome hinges on Gross Margin. The debate is Gross Margin — a fundamental call.

Disclosures & Limitations

This report is for informational and research purposes only. It is not personalised investment advice and does not consider any investor's objectives, financial situation, risk tolerance, tax position, or liquidity needs.

• No suitability assessment has been performed for any individual.
• Market data may be delayed or inaccurate; figures are as of the analysis date.
• Model outputs (fair values, targets, scenario probabilities) are estimates and may be wrong.
• Forecasts are uncertain; past performance is not indicative of future returns.
• The author or publisher may hold positions in securities mentioned.
• Users should verify information against primary sources (company filings) before acting.
• Investing involves risk of loss; there is no guarantee any target price is achieved.
• Ratings follow a defined research methodology (12-month expected-return thresholds), not individual circumstances.